Aim: Aim of this study was to evaluate the possible association between the metabolic abnormalites characteristic of the Metabolic Syndrome (MetS), according to NCEP-ATPIII, and the prostatic adenomyomatosis or prostate cancer. Methods: 111 patients were enrolled. Subjects underwent a medical examination including digital rectal exploration (DRE), prostate-specific antigen (PSA) determination and, when indicated a transrectal ultrasonography (TRUS) with prostate biopsy. Patients were subsequently divided into 3 groups: subjects with DRE -, TRUS - and PSA < 4 ng/ml (controls, n=24); patient with histological diagnosis of prostate cancer (PC n=32) and patient with prostatic alterations (DRE+ and/or TRUS + and/or PSA > 4 mg/dl) without histological evidence of prostate cancer (DRE/TRUS/PSA+/Bio- n=55). Results: Total cholesterol, LDL-chol and not-HDL-chol were significantly lower in the DRE/TRUS/PSA +/Bio - group compared to controls and PC group. Triglycerides, glycemia, HDL-chol and insulin sensitivity, estimated with HOMA index, were not significantly different however the prevalence of the glycemic criteria for MetS was significantly higher in the DRE/TRUS/PSA +/biopsy - group. The three groups did not differ in terms of adiposity index except for BMC which was significantly lower in PC group. Prevalence of MetS was similar in the 3 groups however subjects in the DRE/TRUS/PSA+ Bio - group met a significantly higher number of diagnostic criteria for MEtS. Conclusions: Our results support a possible association between MetS and benign prostatic hyperplasia while metabolic abnormalities do not seem to be associated with prostate cancer.
Role of metabolic abnormalities of the metabolic syndrome in prostatic adenomyomatosis and prostate cancer.
LODI, Elisa;SANZ MOLINA, Juana Maria;DALLA NORA, Edoardo;MORIERI, Mario Luca;ZULIANI, Giovanni;PASSARO, Angelina
2012
Abstract
Aim: Aim of this study was to evaluate the possible association between the metabolic abnormalites characteristic of the Metabolic Syndrome (MetS), according to NCEP-ATPIII, and the prostatic adenomyomatosis or prostate cancer. Methods: 111 patients were enrolled. Subjects underwent a medical examination including digital rectal exploration (DRE), prostate-specific antigen (PSA) determination and, when indicated a transrectal ultrasonography (TRUS) with prostate biopsy. Patients were subsequently divided into 3 groups: subjects with DRE -, TRUS - and PSA < 4 ng/ml (controls, n=24); patient with histological diagnosis of prostate cancer (PC n=32) and patient with prostatic alterations (DRE+ and/or TRUS + and/or PSA > 4 mg/dl) without histological evidence of prostate cancer (DRE/TRUS/PSA+/Bio- n=55). Results: Total cholesterol, LDL-chol and not-HDL-chol were significantly lower in the DRE/TRUS/PSA +/Bio - group compared to controls and PC group. Triglycerides, glycemia, HDL-chol and insulin sensitivity, estimated with HOMA index, were not significantly different however the prevalence of the glycemic criteria for MetS was significantly higher in the DRE/TRUS/PSA +/biopsy - group. The three groups did not differ in terms of adiposity index except for BMC which was significantly lower in PC group. Prevalence of MetS was similar in the 3 groups however subjects in the DRE/TRUS/PSA+ Bio - group met a significantly higher number of diagnostic criteria for MEtS. Conclusions: Our results support a possible association between MetS and benign prostatic hyperplasia while metabolic abnormalities do not seem to be associated with prostate cancer.I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
